What Happened?
Shares of blood products company Haemonetics (NYSE:HAE) jumped 12.4% in the morning session after CSL Plasma announced intentions to complete the deployment of NexSys PCS devices and disposables across all existing U.S. plasma collection centers by the close of 2027.
The full rollout broadens the implementation of Haemonetics' NexSys PCS technology across CSL Plasma's U.S. collection infrastructure. Meanwhile, Haemonetics affirmed that it is keeping its fiscal 2027 financial guidance unchanged ahead of its second-quarter earnings call scheduled for November 2026. Securing full deployment across an entire existing center network signals strong partner commitment to the device platform, which may reassure investors regarding multi-year demand for its proprietary collection equipment and consumable supplies.
Is now the time to buy Haemonetics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Haemonetics’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for Haemonetics and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 22.1% on the news that the company reported third-quarter results that surpassed analyst expectations and raised its full-year financial guidance. The medical technology firm posted adjusted earnings of $1.27 per share on revenue of $327.3 million, with both figures comfortably beating Wall Street's forecasts. While total revenue declined 5.3% year-on-year, the company's organic revenue fell only 1.8%, which was significantly better than the 5.3% decline analysts had anticipated, signaling resilience in its core operations. Furthermore, Haemonetics demonstrated strong profitability and cash generation. Its operating margin expanded to 17.9% from 15% in the same quarter last year, and free cash flow was a robust $106.3 million. Bolstered by the strong performance, management lifted its full-year adjusted earnings per share guidance to a midpoint of $4.90.
Haemonetics is up 43.8% since the beginning of the year, and at $114.99 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Haemonetics’s shares 5 years ago would now be looking at an investment worth $1,704.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.